CEO's Perspective


Reverse Splits and Uplisting
“We view uplisting to NASDAQ — one of our corporate goals for 2015 — as an important and positive step in InVivo’s long-term growth strategy. One of the quantitative requirements for initial listing is that the closing price of our stock must be above $3.00 for 5 days. Properly executing our planned reverse stock split allows us to fulfill this crucial price requirement and reap the benefits of being on NASDAQ. ” For full text, click here.

CEO Mark Perrin, InVivo Therapeutics , March 24, 2015

Research & Clinical Development Preview

_0006_Pressure ulcers

Click here to learn more

Menu